|Bid||19.13 x 1000|
|Ask||20.50 x 2900|
|Day's Range||18.69 - 20.31|
|52 Week Range||11.30 - 34.51|
|Beta (5Y Monthly)||2.16|
|PE Ratio (TTM)||10.68|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CDMO
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
On today's call, we have Nick Green, president and CEO; Dan Hart, chief financial officer; and Matt Kwietniak, Avid's chief commercial officer. Today, we will be providing an overview of Avid Bioservices contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31, 2022.
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?